Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may predict which triple-negative breast cancers will return

NCT ID NCT06418126

Knowledge-focused Sponsor: Centre Paul Strauss Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether measuring certain inflammatory proteins (cytokines) in the blood during radiotherapy can help predict which triple-negative breast cancer patients are likely to have their cancer come back. Researchers will take blood samples from 15 women before and during radiotherapy and track their health for up to 5 years. The goal is to find a simple way to identify high-risk patients who might need extra treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a blood test that identifies which TNBC patients are at high risk of recurrence after radiotherapy.
What could go wrong
This is a very small, early-stage study with only 15 participants. It is observational and does not test a new treatment, so results may not lead to a usable test.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Aug 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Women with TNBC breast cancer who meet the following criteria: * Women aged 18 and over; * Any tumor size (pT stage); * Regional lymph node pN0 to pN3; * Patient with pathologically confirmed TNBC (estrogen and progesterone receptor negative and HER2 negative); * Neo- or adjuvant chemotherapy followed by radiotherapy; * No evidence of distant metastasis at time of diagnosis; * Primary tumor removed by conservative surgery with negative margins; * Patient covered by the French social security system (for French patients). Exclusion Criteria: * Distant metastasis at the time of diagnosis; * Pregnant or breast-feeding women; * Woman deprived of liberty, under guardianship or trusteeship. * Patient unable to give consent * Patient unable to speak French * Patients unable to undergo regular long-term surveillance.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Triple-negative breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Triple-negative breast cancer

Contacts and locations

Locations

  • Institut de cancérologie Strasbourg europe

    Strasbourg, 67033, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.